Current Management of Serious Infections due to Vancomycin-resistant Enterococci.

Vancomycin-resistant enterococci (VRE) are major health care-associated pathogens and significantly contribute to patient morbidity and mortality, particularly in immunocompromised and critically ill patients. The clinical management of VRE infections is challenging due to limited therapeutic options and the paucity of high quality clinical data to guide management. Delays in initiating appropriate therapy has proven to have significant impact in VRE-associated bloodstream infections. This review summarizes the current evidence on treatment strategies for serious VRE infections, incluiding bacteremia and endocarditis, as well as emerging treatment strategies for these recalcitrant organisms.